Changes in blood pressure may occur secondary to weight loss
This also depends on how your body reacts to the medication, but clinical trials showed that after 24 weeks (around six months), the average participant on higher doses of retatrutide lost close to 18% of their body weight
Retatrutide Retatrutide ( LY-3437943 ) is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company
[4] As a result, GLP-1 agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia syndrome type 2 (MEN 2), a genetic disorder that increases the risk of certain types of tumors
In many cases, the drugs are only covered if you have type 2 diabetes
A spokeswoman, Kathleen Makela, said Point32Health, which operates Harvard Pilgrim Health Plan and Tufts Health Plan, had no immediate plans to restrict GLP-1 coverage for weight loss